Bicycle Therapeutics

Historical price data

Bicycle Therapeutics aims to become a world-leading solid tumor medicines company by leveraging its proprietary Bicycle® platform to create precision-guided therapeutics. Its core technology enables the rapid discovery and development of constrained peptides with high affinity and selectivity for challenging targets. The company is progressing multiple clinical-stage oncology assets and has established creative collaborative relationships to expand its technology into anti-infective, cardiovascular, and CNS diseases.

Proprietary Bicycle® platform for discovering and developing fully synthetic, constrained peptides that combine the pharmacology of antibodies with the pharmacokinetic properties of small molecules.

Bicycle competes with ADC developers (e.g., AstraZeneca/Daiichi Sankyo) and other peptide therapeutics companies (e.g., PeptiDream). Its key differentiation is the small size, rapid tissue penetration, and tunable pharmacokinetics of its molecules, potentially offering advantages in targeting solid tumors and creating novel multi-specific therapeutics.